相似文献
1
The Biology and Therapeutic Potential of the Src-YAP Axis in Non-Small Cell Lung Cancer (NSCLC).
Cancers (Basel). 2022 Dec 14;14(24):6178. doi: 10.3390/cancers14246178.
2
The Crosstalk between Src and Hippo/YAP Signaling Pathways in Non-Small Cell Lung Cancer (NSCLC).
Cancers (Basel). 2020 May 26;12(6):1361. doi: 10.3390/cancers12061361.
3
Metformin-repressed miR-381-YAP-snail axis activity disrupts NSCLC growth and metastasis.
J Exp Clin Cancer Res. 2020 Jan 6;39(1):6. doi: 10.1186/s13046-019-1503-6.
4
Inhibition of yes-associated protein suppresses migration, invasion, and metastasis in non-small cell lung cancer in vitro and in vivo.
Clin Exp Med. 2022 May;22(2):221-228. doi: 10.1007/s10238-021-00738-4. Epub 2021 Jul 1.
5
Epidermal Growth Factor Receptor (EGFR) Pathway, Yes-Associated Protein (YAP) and the Regulation of Programmed Death-Ligand 1 (PD-L1) in Non-Small Cell Lung Cancer (NSCLC).
Int J Mol Sci. 2019 Aug 5;20(15):3821. doi: 10.3390/ijms20153821.
6
Melatonin Downregulates PD-L1 Expression and Modulates Tumor Immunity in KRAS-Mutant Non-Small Cell Lung Cancer.
Int J Mol Sci. 2021 May 26;22(11):5649. doi: 10.3390/ijms22115649.
7
Expression characteristics of AXL and YAP in non-small cell lung cancer and prognostic importance.
Int J Clin Exp Pathol. 2018 Jul 1;11(7):3357-3365. eCollection 2018.
8
Expression of Yes-associated protein in non-small cell lung cancer and its relationship with clinical pathological factors.
Chin Med J (Engl). 2012 Nov;125(22):4003-8.
9
The novel FAT4 activator jujuboside A suppresses NSCLC tumorigenesis by activating HIPPO signaling and inhibiting YAP nuclear translocation.
Pharmacol Res. 2021 Aug;170:105723. doi: 10.1016/j.phrs.2021.105723. Epub 2021 Jun 9.
10
The Role of Yes-Associated Protein (YAP) in Regulating Programmed Death-Ligand 1 (PD-L1) in Thoracic Cancer.
Biomedicines. 2018 Dec 7;6(4):114. doi: 10.3390/biomedicines6040114.
引用本文的文献
1
Inhibition of Src Attenuates Stemness and Reverses Cisplatin Resistance of Non-Small-Cell Lung Cancer Cells.
Bull Exp Biol Med. 2025 Feb;178(4):460-466. doi: 10.1007/s10517-025-06356-4. Epub 2025 Mar 29.
本文引用的文献
1
Mechanobiology of solid tumors.
Biochim Biophys Acta Mol Basis Dis. 2022 Dec 1;1868(12):166555. doi: 10.1016/j.bbadis.2022.166555. Epub 2022 Sep 20.
2
An Overview of the Role of Mechanical Stretching in the Progression of Lung Cancer.
Front Cell Dev Biol. 2021 Dec 24;9:781828. doi: 10.3389/fcell.2021.781828. eCollection 2021.
3
The Crosstalk between Src and Hippo/YAP Signaling Pathways in Non-Small Cell Lung Cancer (NSCLC).
Cancers (Basel). 2020 May 26;12(6):1361. doi: 10.3390/cancers12061361.
4
YAP/TAZ: Drivers of Tumor Growth, Metastasis, and Resistance to Therapy.
Bioessays. 2020 May;42(5):e1900162. doi: 10.1002/bies.201900162. Epub 2020 Mar 4.
5
Treatment-Induced Tumor Dormancy through YAP-Mediated Transcriptional Reprogramming of the Apoptotic Pathway.
Cancer Cell. 2020 Jan 13;37(1):104-122.e12. doi: 10.1016/j.ccell.2019.12.006.
6
CDK7 regulates organ size and tumor growth by safeguarding the Hippo pathway effector Yki/Yap/Taz in the nucleus.
Genes Dev. 2020 Jan 1;34(1-2):53-71. doi: 10.1101/gad.333146.119. Epub 2019 Dec 19.
7
A new FGFR inhibitor disrupts the TGF-β1-induced fibrotic process.
J Cell Mol Med. 2020 Jan;24(1):830-840. doi: 10.1111/jcmm.14793. Epub 2019 Nov 6.
8
SRC and MEK Co-inhibition Synergistically Enhances the Anti-tumor Effect in Both Non-small-cell Lung Cancer (NSCLC) and Erlotinib-Resistant NSCLC.
Front Oncol. 2019 Jul 30;9:586. doi: 10.3389/fonc.2019.00586. eCollection 2019.
9
Non-Small Cell Lung Cancer: Epidemiology, Screening, Diagnosis, and Treatment.
Mayo Clin Proc. 2019 Aug;94(8):1623-1640. doi: 10.1016/j.mayocp.2019.01.013.
10
Src-mediated crosstalk between FXR and YAP protects against renal fibrosis.
FASEB J. 2019 Oct;33(10):11109-11122. doi: 10.1096/fj.201900325R. Epub 2019 Jul 12.
Zotero 插件